BioAtla Investor Presentation Deck

Phase 2 CAB-ROR2 (BA3021) Summary of Dosing Regimens for Clinical Studies Indication NSCLC* Melanoma Head and Neck bicatla Dose Q2W monotherapy Q2W in combo w/ nivolumab 3Q4W monotherapy Q2W monotherapy Q2W monotherapy 2Q3W monotherapy *Currently no plans to internally explore NSCLC further at this time NSCLC = non small cell lung cancer Maximum Patient # N~ 20 N~ 20 N~ 20 N~ 25 N~ 20 N~ 20 Status ✓ ✓ Not advancing; suboptimal compliance Fully enrolled Not advancing Fully enrolled BioAtla| Overview 50

View entire presentation